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Background: The purpose of this study was to assess the in vivo ability of glucosaminic 
  acid-cobalt (II) chelate to reduce glycemia.
Methods: Different concentrations of chelate solution were administrated to mice with  diabetes 
induced by streptozotocin. 
Results: Daily oral administration of chelate solution 0.4 mL at various concentrations (0.32–
0.4 g/mL) led to reduction in water intake by the diabetic mice after 5 days of treatment, with a 
subsequent reduction in glucose levels observed 2 weeks later. Daily food intake was related to 
both chelate concentration as well as glycemia reduction. The food intake of mice treated with 
glucosaminic acid-cobalt (II) chelate solution was 1.5-fold that of untreated mice.
Conclusion: Glucosaminic acid-cobalt chelate was effective as an antidiabetes agent; its efficacy 
was proportional to treatment period .The chelated form expressed much less toxicity compared 
to cobalt only, and stimulated subsequent food intake after daily administration.
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Introduction
Diabetes mellitus, often simply referred to as diabetes, is a group of metabolic diseases 
in which a person has high blood sugar, either because the body does not produce 
enough insulin, or because cells do not respond to the insulin that is produced. This high 
blood sugar produces the classical symptoms of polyuria, polydipsia, and polyphagia.1 
The chronically higher level of blood sugar generates damage in various organs, 
  especially the eyes, kidneys, nerves, and heart, as well as the blood vessels.
The number of people with diabetes is expected to increase dramatically in the 
coming decades, rising to 380 million people by 2025. Developed countries have higher 
prevalence rates than developing countries, but the latter will be hit hardest by the 
diabetes epidemic. Increased urbanization, westernization, and economic development 
in developing countries have already contributed to a substantial rise in diabetes.2,3 The 
development of diabetes complications contributes substantially to the elevated death 
rates in diabetic patients. The mechanism by which diabetes leads to these complica-
tions is complex and not yet fully understood, but involves the direct toxic effects of 
high glucose levels, along with the impact of elevated blood pressure, abnormal lipid 
levels, and oxidative stress, as well as being a chronic inflammatory condition.4
Type 1 (insulin-dependent) diabetes mellitus is characterized by loss of the insulin-pro-
ducing beta cells of the islets of Langerhans in the pancreas, leading to insulin deficiency. 
This type of diabetes can be further classified as immune-mediated or idiopathic.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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The majority of type 1 diabetes is of an immune-mediated 
nature, whereby beta cell loss is a T cell-mediated autoim-
mune attack.5,6 Cobalt has been demonstrated to boost the 
effects of insulin and its action.6 The efficiency of cobalt as 
an antidiabetic agent has been proven. However, the use of 
cobalt in its single and pure form may be lethal to patients.6,7 
Therefore, it is crucial to implement research to identify new 
agents that can reduce the potential toxicity of cobalt without 
impacting on its efficacy.
In the present work we evaluated the ability of   glucosaminic 
acid-cobalt (II) chelate to lower glycemia levels in mice with 
streptozotocin-induced diabetes.
Materials and methods
Animals
Thirty male mice with a body weight of 16–18 g were 
purchased from the Shanghai Laboratory Animal Center 
(Shanghai, China). The mice were housed five per cage at 
room temperature regulated to 22–24°C in the experimental 
animal facility of the School of Medicine and Pharmaceutics, 
Jiangnan University. They were fed for 1 week to standardize 
body weight at the minimum value of 20 g. Diabetes was 
induced by injection of freshly prepared concentrated strep-
tozotocin (7.5 mg/mL) in sodium citrate buffer. Each mouse 
was injected with 0.2 mL in the tail vein for 5 consecutive 
days. One week after injection, blood samples were taken 
from the caudal vein after the mice were anesthetized. Fasting 
blood glucose and total body weights were recorded, and the 
mice were divided into three groups. The experimental pro-
tocol conformed with the ethics regulations and procedures 
instituted by the School of Medicine and Pharmaceutics at 
Jiangnan University.
experimental design
The diabetic mice were divided into three groups (n = 10 per 
group), ie, Group A (fed as for Groups B and C except that 
instead of the chelate solution they were given 0.4 mL/day 
of double-distilled water), Group B (given 0.4 mL/day of 
0.32 g/mL chelate solution), and Group C (given 0.4 mL/day 
of 0.4 g/mL chelate solution). The food and water intake of all 
three groups was recorded daily. Body weight and blood glu-
cose levels were determined every week. The experiment was 
carried out for 5 weeks after streptozotocin administration. 
At the end of the experiment and after 12 hours of fasting, all 
animals were sacrificed. Blood samples were collected from 
the heart, placed on ice, and centrifuged within 10 minutes 
of sample collection. Serum was stored at −20°C for 7 days 
before analysis.
Statistical analysis
Results were expressed as the mean of triplicate   experiments. 
One-way analysis of variance with a Student’s   Newman–Keuls 
post hoc comparison was used to test for statistical   significance, 
set at P , 0.05.
Results and discussion
effect of chelate on body weight  
and daily water/food intake
The body weight of the diabetic mice during treatment 
increased to a maximum individual value of 27 g by the end 
of the third week of the experiment (Figure 1). However, 
this value did not decrease at the final week. The stability in 
body weight was in contrast with previous work,7 and might 
be attributed to the fact that chelating cobalt to glucosaminic 
acid reduced its toxicity and potential side effects, including 
diarrhea, which is mostly responsible for the decrease in body 
weight. No significant (P , 0.05) differences in body weight 
were seen in the treated mice. However, their values were 
significantly (P , 0.05) higher than that of the control mice 
by the fifth week of the experiment. This relative difference 
might be related to the decrease in food intake as a result of 
the increase in blood sugar over the treatment period.
Tables 1 and 2 show the analytical data for water and 
food intake, respectively, in the different groups of mice 
used in this study.
The volume of water intake in Group A was higher and 
continued to increase up to the end of the experiment, and was 
estimated to be three-fold that of Group C. In Group B (receiv-
ing 0.4 mL/day of chelate 0.32 g/mL solution), a decrease 
in daily water intake was observed after the first week of 
treatment, while in Group C (receiving 0.4 mL/day of che-
late 0.4 g/mL solution), a decrease in daily water intake was 
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observed after 5 days of treatment, but the value was still higher 
compared with water intake prior to   induction of diabetes.
Major differences were observed in terms of food 
intake. Treated mice had an over 1.5-fold higher food intake 
  compared with diabetic mice throughout the experiment. This 
was in opposition to the results reported by Yagmaei et al8 
indicating a decrease in food intake for treated   animals. 
The relative increase in food intake was observed from 
the sixth day of treatment, and this generated a difference 
in body weight between treated and untreated mice. The 
relative increase in food intake might be due to the fact that 
administration of a higher dose of glucosaminic acid-cobalt 
chelate enhanced relaxation in diabetic mice. It has been 
shown that cobalt or its chelated form might attenuate the 
vasoconstrictor response.9
glycemia-lowering effect of chelate
The glycemia-lowering effect of chelate on mice with 
streptozotocin-induced diabetes was determined weekly for 
a period of 5 weeks. At indicated times, blood samples were 
taken for glycemia level determination using (ACCU-CHEK 
Active, Roche Diagnostics GmbH, Mannheim, Germany). 
Figure 2 describes the glycemia-lowering effect of the chelate 
for the three groups of mice in this experiment. As expected, 
the glycemia level for treated mice was higher and kept 
increasing until the end of the experiment. The glycemia 
concentration exceeded 34 mmol/L in two mice. At the end 
of the first week of treatment, no significant decrease was 
observed for glycemia in treated mice. However, in contrast 
with Group A mice, glycemia values were relatively stable 
in the groups of diabetic treated mice.
The effect of administration of chelate at a higher con-
centration (1.5 g/mL) was dramatic in diabetic mice and we 
reached this finality in a pre-experiment study. Ybarra et al7 
concluded that the toxicity of cobalt at a higher dose led to 
death. In the case of the chelated form, the lethal toxicity at 
the higher dose might be due to the fact that additional intake 
was conjugated to the previous unused dose. Mice present 
with a smaller digestion system compared with rats or other 
larger animals, and thus take longer to deplete their previ-
ous intake.
When the higher dose was administered, the mice did not 
exhaust the previous dose, and therefore, when a new dose 
was administered and conjugated with the rest of the previous 
dose, and thereby increasing the total daily dose, death ensued. 
In comparison with previous work on use of cobalt only, we 
conclude that efficiency of the chelate in diabetic animals was 
significant at certain doses almost 1 week after treatment, while 
the single administration of cobalt chloride7 generated efficient 
results after just 3 days of treatment. This finding is in agree-
ment with numerous works on the glycemia-lowering effect 
of metal ions,9–11 but the mechanism is still obscure. At the end 
of 5 weeks of treatment, all the mice were still diabetic but the 
blood sugar for treated mice had decreased dramatically. In 
case of Group C (receiving the daily higher dose), the glycemia 
level determined at the fifth week (12.89 mmol/L) was closer to 
the value in a nondiabetic animal without fasting. For Groups B 
and C, no significant difference in blood sugar was observed 
from the fourth week of study onwards (P , 0.05).
Conclusion
The use of glucosaminic acid-cobalt chelate as a glycemia-
lowering drug was effective. Its efficacy was proportional to 
the treatment duration. The daily intake of this chelate was 
nontoxic at a reasonable dose and stimulated subsequent 
food intake. The use of cobalt only3 in antidiabetic treatment 
appears to be less time-consuming, but has higher toxicity 
compared with the chelated form.
Table 1 Water intake in rats with streptozotocin-induced diabetes
Water intake (mL)
5th day 10th day 15th day 20th day 25th day 30th day 35th day
group A 128.12 130.43 140.76 143.23 152.91 161.27 156.97
group B 130.02 108.31 97.37 95.08 86.11 63.33 54.61
group c 112.21 98.11 76.66 63.53 52.71 44.55 43.68
Table 2 Food intake in mice with streptozotocin-induced diabetes
Food intake (g)
5th day 10th day 15th day 20th day 25th day 30th day 35th day
group A 106.08 87.05 83.40 79.15 63.38 60.63 61.81
group B 103.12 112.32 127.32 108.34 101.26 103.43 113.37
group c 101.02 109.21 129.01 121.01 109.63 111.31 112.48Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
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